Lumosa Therapeutics Co., Ltd. (TPEX:6535)

Lumosa Therapeutics Financials Overview

Financials in millions TWD. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	31.42	35.83	39.15	56.92	26.64	17.36
Revenue Growth	-27.92%	-8.49%	-31.21%	113.63%	53.45%	-19.81%
Gross Profit Gross Profit Growth	18.5	21.87	17.71	41.48	14.56	9.89
Operating Income Operating Income Growth	-293.56	-333.49	-357.12	-375.78	-305.92	-430.28
Net Income Net Income Growth	-356.04	-340.54	-424.78	-238.04	-494.66	95.95
Earnings Per Share EPS Growth	-2.14	-2.05	-2.60	-1.47	-3.05	0.64
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Taiwan Taiwan Growth	21.98	22.37	27.33	15.41	21.24	15.04
Asia Asia Growth	9.44	13.46	11.65	25.61	2	2.33
America America Growth	-	-	0.18	7.56	3.19	-
Total Total Growth	31.42	35.83	39.15	56.92	26.64	17.36

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	747.43	798.34	1,353	844.31	1,185	1,452
Total Debt Total Debt Growth	5.2	6.92	8.48	12.61	4.69	11.49
Net Cash (Debt) Net Cash Growth	742.23	791.42	1,344	831.7	1,180	1,441
Net Cash Growth	-41.02%	-41.13%	61.64%	-29.51%	-18.10%	14.89%
Net Cash Per Share Net Cash Per Share Growth	4.47	4.76	8.22	5.12	7.26	9.55

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	-331.31	-360.5	-296.33	-328.21	-300.46	-452.6
Capital Expenditures CapEx Growth	-0.67	-0.67	-0.45	-14.32	-2.29	-0.09
Free Cash Flow Free Cash Flow Growth	-331.98	-361.16	-296.78	-342.53	-302.74	-452.69
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	58.89%	61.05%	45.24%	72.88%	54.65%	56.96%
Operating Margin	-934.37%	-930.73%	-912.09%	-660.23%	-1148.26%	-2478.27%
Pretax Margin	-1152.05%	-967.37%	-1115.69%	-439.39%	-1893.42%	552.62%
Profit Margin	-1133.24%	-950.41%	-1084.91%	-418.23%	-1856.70%	552.62%
FCF Margin	-1056.65%	-1007.96%	-757.97%	-601.82%	-1136.33%	-2607.34%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 7, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	-	-	-	-	-	63.75
PS Ratio	480.31	914.46	1078.41	197.97	241.17	352.32

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 7, 2026

Data Sources Report a data error